28411139|t|The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk
28411139|a|Although the implantable cardioverter-defibrillator (ICD) remains the main therapy for Brugada syndrome (BrS), it does not reduce life-threatening ventricular arrhythmia. Based on pathophysiologic mechanisms, hydroquinidine (HQ) has been suggested for effective prevention of arrhythmia. The purpose of this study was to provide evidence -based data supporting HQ use to prevent life-threatening ventricular arrhythmia in high-risk patients with BrS. We performed a prospective multicenter randomized (HQ vs placebo) double-blind study with two 18- month crossover phases in patients with BrS and implanted with an ICD. Among the 50 patients enrolled (mean age 47.0 ± 11.4 years, 42 [84%] male), 26 (52%) fully completed both phases. Thirty-four (68%) presented HQ -related side effects, mainly gastrointestinal, which led to discontinuation of the therapy in 13 (26%). HQ lengthened the QTc interval (409 ± 32 ms vs 433 ± 37 ms; P = .027) and increased repolarization dispersion as evaluated by Tpe max in precordial leads (89 ± 15 ms vs 108 ± 27 ms; P <.0001) with no significant changes in J-point elevation. During the 36- month follow-up, 1 appropriate ICD shock (0.97% event per year), 1 self - terminating ventricular fibrillation, and 1 inappropriate ICD shock occurred under placebo therapy. No arrhythmic events were reported under HQ therapy. Although HQ seems to be effective in preventing life-threatening ventricular arrhythmia, it could not be an alternative for ICD implantation. Its frequent side effects greatly reduce its probable compliance and therefore do not reveal a significant effect. HQ increases repolarization dispersal with no changes in BrS pattern, which could indicate a more complex action of HQ than its Ito blocking effect alone.
28411139	4	16	QUIDAM study	T062	C0033522
28411139	18	32	Hydroquinidine	T109,T121	C0063103
28411139	33	40	therapy	T061	C0087111
28411139	49	59	management	T058	C0376636
28411139	63	79	Brugada syndrome	T047	C1142166
28411139	80	88	patients	T101	C0030705
28411139	97	107	arrhythmic	T047	C0085612
28411139	108	112	risk	T078	C0035647
28411139	126	164	implantable cardioverter-defibrillator	T074	C0162589
28411139	166	169	ICD	T074	C0162589
28411139	188	195	therapy	T061	C0087111
28411139	200	216	Brugada syndrome	T047	C1142166
28411139	218	221	BrS	T047	C1142166
28411139	243	259	life-threatening	T033	C2826244
28411139	260	282	ventricular arrhythmia	T047	C0085612
28411139	293	309	pathophysiologic	T169	C0205463
28411139	310	320	mechanisms	T169	C0441712
28411139	322	336	hydroquinidine	T109,T121	C0063103
28411139	338	340	HQ	T109,T121	C0063103
28411139	375	385	prevention	T061	C0679698
28411139	389	399	arrhythmia	T047	C0085612
28411139	421	426	study	T062	C2603343
28411139	442	450	evidence	T078	C3887511
28411139	458	462	data	T078	C1511726
28411139	474	476	HQ	T109,T121	C0063103
28411139	477	480	use	T169	C0457083
28411139	492	508	life-threatening	T033	C2826244
28411139	509	531	ventricular arrhythmia	T047	C0085612
28411139	535	544	high-risk	T033	C0332167
28411139	545	553	patients	T101	C0030705
28411139	559	562	BrS	T047	C1142166
28411139	579	648	prospective multicenter randomized (HQ vs placebo) double-blind study	T062	C0013072
28411139	662	667	month	T079	C0439231
28411139	668	684	crossover phases	T079	C0205390
28411139	688	696	patients	T101	C0030705
28411139	702	705	BrS	T047	C1142166
28411139	710	719	implanted	T061	C0021107
28411139	728	731	ICD	T074	C0162589
28411139	746	754	patients	T101	C0030705
28411139	770	773	age	T032	C0001779
28411139	786	791	years	T079	C0439234
28411139	802	806	male	T032	C0086582
28411139	839	845	phases	T079	C0205390
28411139	875	877	HQ	T109,T121	C0063103
28411139	887	899	side effects	T046	C0879626
28411139	908	924	gastrointestinal	T029	C0809794
28411139	939	969	discontinuation of the therapy	T061	C4288399
28411139	983	985	HQ	T109,T121	C0063103
28411139	986	996	lengthened	T169	C0392744
28411139	1001	1013	QTc interval	T201	C0489625
28411139	1067	1081	repolarization	T042	C3537202
28411139	1082	1092	dispersion	T082	C0332624
28411139	1109	1116	Tpe max	T033	C0239242
28411139	1120	1136	precordial leads	T074	C0180616
28411139	1206	1213	J-point	T201	C3871156
28411139	1214	1223	elevation	T082	C0702240
28411139	1240	1245	month	T079	C0439231
28411139	1246	1255	follow-up	T058	C1522577
28411139	1271	1274	ICD	T074	C0162589
28411139	1275	1280	shock	T046	C0036974
28411139	1288	1293	event	T051	C0441471
28411139	1298	1302	year	T079	C0439234
28411139	1307	1311	self	T078	C0036588
28411139	1314	1325	terminating	T079	C2746065
28411139	1326	1350	ventricular fibrillation	T047	C0042510
28411139	1372	1375	ICD	T074	C0162589
28411139	1376	1381	shock	T046	C0036974
28411139	1397	1412	placebo therapy	T061	C0032042
28411139	1417	1427	arrhythmic	T047	C0085612
28411139	1428	1434	events	T051	C0441471
28411139	1455	1457	HQ	T109,T121	C0063103
28411139	1458	1465	therapy	T061	C0087111
28411139	1476	1478	HQ	T109,T121	C0063103
28411139	1504	1514	preventing	T061	C0679698
28411139	1515	1531	life-threatening	T033	C2826244
28411139	1532	1554	ventricular arrhythmia	T047	C0085612
28411139	1575	1586	alternative	T077	C1523987
28411139	1591	1594	ICD	T074	C0162589
28411139	1595	1607	implantation	T061	C0021107
28411139	1622	1634	side effects	T046	C0879626
28411139	1704	1715	significant	T078	C0750502
28411139	1716	1722	effect	T080	C1280500
28411139	1724	1726	HQ	T109,T121	C0063103
28411139	1737	1751	repolarization	T042	C3537202
28411139	1752	1761	dispersal	T082	C0332624
28411139	1781	1784	BrS	T047	C1142166
28411139	1785	1792	pattern	T081	C0449782
28411139	1822	1829	complex	T080	C0439855
28411139	1830	1836	action	T052	C3266814
28411139	1840	1842	HQ	T109,T121	C0063103
28411139	1856	1864	blocking	T169	C0332206
28411139	1865	1871	effect	T080	C1280500